Biagio Ricciuti: Great conversation on the role of ICI in patients with NSCLC and driver mutations

Biagio Ricciuti shared a post by Narjust Florez on X, adding:   ,

“I had a great conversation with the amazing Narjust Florez and Erin Schenk on the role of ICI in patients with NSCLC (Non-small cell lung cancer) and driver mutations.

The potential of immune therapies has yet to be realized for most of oncogene-positive lung cancers. We need to explore options beyond checkpoint inhibitors.”

Quoting Narjust Florez’s post:

“I hope you are ready for this discussion with Drs. Erin Schenk and Biagio Ricciuti.

I learned so much only in the first 5 minutes of this conversation about the use of IO in patients with NSCLC (Non-small cell lung cancer) and driver mutations.

Including:

-Toxicity
-Importance of NGS
-Prognostic and predictive markers
-The impact of tumor microenvironment

Lung Cancer is Considered the official IASLC (The International Association for the Study of Lung Cancer) podcast.”

Source: Biagio Ricciuti/X and Narjust Florez/X

Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School. His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.

Narjust Florez is the Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Brigham Cancer Center. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer.

In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine, and medical education.